ImmunoPrecise Antibodies Stock Quote IPA - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

6.50

Bid

6.31

Ask

6.75

Volume

0.00 Day's Range 0.00

6.50 52 Week Range 6.50

Market Cap

175.136M

Previous Close

6.50

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

Shares Outstanding

26,944,000

Dividend Yield

PE Ratio

-0.63

Earnings Per Share (EPS)

-1.01

Revenue

24.52M

Net Profit

-27.18M

Sector

Pharmaceutical Preparations

Industry

Miscellaneous Metal Ores,nec

Website

www.immunoprecise.com

Headquarters

Victoria, British Columbia, Can

Founded

2016

ImmunoPrecise Antibodies Ltd is listed in the Pharmaceutical Preparations sector of the TSX Venture Exchange with ticker IPA. The last closing price for ImmunoPrecise Antibodies was $6.50. Over the last year, ImmunoPrecise Antibodies shares have traded in a share price range of $ 6.50 to $ 6.50.

ImmunoPrecise Antibodies currently has 26,944,000 shares outstanding. The market capitalization of ImmunoPrecise Antibodies is $175.14 million. ImmunoPrecise Antibodies has a price to earnings ratio (PE ratio) of -0.63.

IPA's Subsidiary BioStrand Secures Second VLAIO Research Grant

IPA's Subsidiary BioStrand Secures Second VLAIO Research GrantIPA subsidiary BioStrand receives grant to expand LENSai platform by linking HYFTs™ with 3D protein structure and...

IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue - Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings

IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue – Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and...

IPA Announces Agreement to Acquire BioStrand BV - Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence

IPA Announces Agreement to Acquire BioStrand BV - Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence New Platform...

IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from Defense Health Agency within US Department of Defense

IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from Defense Health Agency within US Department of...

IPA Updates on Investigational New Drug (IND) Enabling Program for PolyTope® TATX-03

IPA Updates on Investigational New Drug (IND) Enabling Program for PolyTope® TATX-03 In vivo, IND enabling evaluations of PolyTope® TATX-03 in animal model show:There were no...

ImmunoPrecise lance le programme d'anticorps candidat TATX-112 pour le traitement du cancer et de la maladie d'Alzheimer

Traitement potentiel de la maladie de Parkinson et d'autres affections neurodégénératives IMMUNOPRECISE ANTIBODIES LTD. (la "Société" ou "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) un chef de file...

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer's Disease

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer's Disease Potential to Treat Parkinson's and Other...

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer’s Disease

Potential to Treat Parkinson’s and Other Neurodegenerative Diseases IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic...

ImmunoPrecise identifie un anticorps unique, le 23-H7, qui démontre une efficacité in vivo, un mécanisme d'action alternat...

L'anticorps bloque l'interaction de liaison DFR/ACE2 par le biais d'un mécanisme d'action alternatif L'anticorps se lie à tous les variants préoccupants testés, probablement parce qu'il cible un...

ImmunoPrecise Identifies a Unique Antibody, 23-H7, That Demonstrates In Vivo Efficacy, an Alternative Mechanism of Action & B...

Blocks the RBD/ACE2 binding interaction indirectly through an alternative mechanism of action Binds to all tested variants of concern, likely because it targets a site other than the mutation...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	6.5	6.5	6.5	0	0	CS
4	0	0	6.5	6.5	6.5	0	0	CS
12	0	0	6.5	6.5	6.5	0	0	CS
26	0	0	6.5	6.5	6.5	0	0	CS
52	0	0	6.5	6.5	6.5	0	0	CS
156	-2.22	-25.4587155963	8.72	8.92	4.52	8343	6.72084343	CS
260	5.91	1001.69491525	0.59	26.25	0.445	77264	3.88625509	CS

Symbol	Price	Vol.
GDNP.HGood Natured Products Inc	$ 0.01 (100.00%)	91.47k
CANSWildpack Beverage Inc	$ 0.01 (100.00%)	36k
ROCKRockridge Resources Ltd	$ 0.015 (50.00%)	10k
MTLOMartello Technologies Group Inc	$ 0.015 (50.00%)	1,000
ACDCAC DC Battery Metals Inc	$ 0.07 (40.00%)	10.03k
NEWUNewtopia Inc	$ 0.005 (-50.00%)	2.05M
NUGNulegacy Gold Corporation	$ 0.005 (-50.00%)	50k
ICMIconic Minerals Ltd	$ 0.01 (-33.33%)	5k
BTVBlueRush Inc	$ 0.01 (-33.33%)	56k
RGRomios Gold Resources Inc	$ 0.01 (-33.33%)	15k
TVITVI Pacific Inc	$ 0.01 (0.00%)	2.35M
NEWUNewtopia Inc	$ 0.005 (-50.00%)	2.05M
AVUAvrupa Minerals Ltd	$ 0.05 (25.00%)	1.63M
ROSRoscan Gold Corporation	$ 0.105 (0.00%)	1.34M
VZLAVizsla Silver Corp	$ 2.67 (3.49%)	934.22k

Symbol

Price

Vol.